Clinical Trials Logo

Spondylitis clinical trials

View clinical trials related to Spondylitis.

Filter by:

NCT ID: NCT00367211 Completed - Clinical trials for Rheumatoid Arthritis

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.

Start date: September 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the incidence of gastric ulcers following administration of either PN 200 or Naproxen in subjects who are at risk for developing NSAID-associated ulcers.

NCT ID: NCT00356356 Completed - Clinical trials for Ankylosing Spondylitis

16.0040 Ankylosing Spondylitis Study

Start date: April 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate extended safety and efficacy of etanercept in adults with Ankylosing Spondylitis.

NCT ID: NCT00328068 Recruiting - Spondyloarthritis Clinical Trials

Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

Start date: July 2006
Phase: N/A
Study type: Observational

Background: Existing criteria for AS/SpA such as mod. New York, ESSG, or Amor criteria for classification and/or diagnosis of spondyloarthritis have limitations when applied to early disease. Moreover, MRI is not part of any of the established criteria and the precise role of MRI in early axial disease has not been fully defined yet. Even less is known about sacroiliac (SI) changes in SpA patients with peripheral symptoms. A pilot study using data from 'paper patients' led to new candidate criteria for early spondyloarthritis. Subsequently, the members of the ASAS International Working Group decided to conduct a prospective multi-centre study to evaluate (validate) the new candidate criteria, and to assess their performance as diagnostic criteria. Aims of the study: 1. To evaluate the new candidate criteria for axial SpA in a multi-centre setting. 2. To assess the potential role of the new candidate criteria to be used as diagnostic criteria. To accomplish this, inclusion of consecutive and undiagnosed patients is mandatory as are longer periods of follow-up . 3. To compare criteria encompassing the whole group of SpA such as ESSG and Amor criteria against criteria which are tailored to either predominant axial disease or predominant peripheral disease. To accomplish this, both patients with predominant axial disease (back pain) but also patient with predominant peripheral disease (arthritis/enthesitis) will be included.

NCT ID: NCT00320619 Completed - Scoliosis Clinical Trials

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

Start date: September 2000
Phase: N/A
Study type: Interventional

Individuals who undergo spine surgery often have a significant loss of blood and may require multiple blood transfusions. Research has shown that epsilon-aminocaproic acid (EACA) may reduce the amount of blood lost during surgery, which would decrease the number of blood transfusions required. This study will evaluate the safety and effectiveness of EACA at reducing blood loss and the need for blood transfusions in individuals undergoing spine surgery.

NCT ID: NCT00298012 Withdrawn - Clinical trials for Spondylitis, Ankylosing

Methotrexate in the Treatment of Axial Spondyloarthritis

Start date: March 2006
Phase: Phase 4
Study type: Interventional

The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.

NCT ID: NCT00273858 Terminated - Clinical trials for Arthritis, Rheumatoid

Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis

Start date: March 2006
Phase: N/A
Study type: Observational

This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly. The improvement of health-related quality of life will also be evaluated.

NCT ID: NCT00265083 Completed - Clinical trials for Spondylitis, Ankylosing

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of subcutaneous injections (under the skin) of golimumab for the treatment of active ankylosing spondylitis [AS(arthritis of the spine)]. Efficacy will be measured by reduction in the signs and symptoms of active AS, including effects on back pain and stiffness, physical function, range of motion in the spine, quality of life, and rate of spine damage or fusion on x-ray.

NCT ID: NCT00247962 Completed - Clinical trials for Ankylosing Spondylitis

Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis

Start date: December 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.

NCT ID: NCT00244166 Recruiting - Clinical trials for Ankylosing Spondylitis

Prednisolone in Active Ankylosing Spondylitis (AS)

Start date: May 2002
Phase: Phase 2/Phase 3
Study type: Interventional

1. to investigate whether steroids are effective in ankylosing spondylitis 2. if steroids are effective to describe how quick they work

NCT ID: NCT00243750 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

Methotrexate in Ankylosing Spondylitis (MTX in AS)

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Assessing the efficacy and tolerability of methotrexate 15mg sc in the first month of treatment- if well tolerated methotrexate 20mg sc in the following 3 months in patients with active anklyosing spondylitis